Cash shortage hurts Mich. biotech, drug-discovery firms

02/5/2009 | Ann Arbor Business Review (Mich.)

Dwindling support from venture capitalists and other funding sources in Michigan is slowing the growth of drug-discovery companies and forcing some biotech businesses to turn further to offering services, industry observers said. David Canter, who used to head Pfizer's operation in Ann Arbor, Mich., said discovery firms could benefit from increased activity in pharmaceutical services, and the state should keep on being an "idea factory" for the life sciences sector.

View Full Article in:

Ann Arbor Business Review (Mich.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Economics & Reimbursement Manager - Transcatheter Heart Valve
Edwards Lifesciences
Irvine, CA
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA